Zencore Biologics is a CDMO provider headquartered in Shanghai, China, with an R&D facility located in Maryland, United States. Zencore offers one-stop-shop services for biologics ranging from pre-clinical research to commercial manufacturing, as well as customized cell culture medium services for mammalian cell-based protein production. The company supports the R&D and production of protein drugs for domestic and global clients, offering services including:
With two CDMO facilities totaling 600,000 sq ft, Zencore provides pilot scale production with 4×200L and 1×500L single-use bioreactors, as well as state-of-the-art commercial GMP manufacturing services with 3×2,000L single-use and 3×5,000L stainless steel bioreactors in separate production suites, followed by corresponding purification, formulation, and fill and finish lines.
The 21st century is the era of biotechnology and biopharmaceutical industries. Rapid advancements in life sciences, technologies, and healthcare have brought numerous previously untreatable diseases under control with a significant improvement in patient survival rates and quality of life. These changes have presented many opportunities and challenges for CROs and CDMOs to support the R&D of biopharmaceutical industries. With the aspiration to contribute to a healthier world, Zencore Biologics was established.
A purposeful enterprise requires a group of professionals with ambition, vision, and passion. Zencore is privileged to work with many experienced entrepreneurs, talented scientists, and skilled engineers who share our common aspirations and values.
Since its establishment in 2017, Zencore has continuously innovated in technologies and bioprocesses to improve operational efficiencies. We have been at the forefront of supporting the growth of biopharmaceutical R&D and have earned a good reputation among our global clients.
With a strong belief in "Of the people, by the people, for the people", we will unleash huge potential and creativity. Adhering to our principles of "Pursue the Truth, Commit the Utmost, Strive for Excellence", and alongside our clients, we will create a better and healthier world.
Jianxin Chen ,CEO of Zencore Biologics Co., Ltd.
Since its establishment in 2017, Zencore Biologics has become the industry leader in large-scale mammalian cell culture technology. Our team has achieved the record high expression level in the fed-batch culture process for antibody production, which currently stands at 15 g/L.
To date, Zencore Biologics has helped customers complete 19 IND and 2 BLA projects, with more than 200 project experiences overall, including 50+ monoclonal antibodies, 30+ bispecific antibodies, 20+ antibody-drug conjugates (ADCs), and 90+ other forms of recombinant proteins.
Adhering to our values of pursuing facts, committing to the utmost, and striving for excellence, we aim to deliver the best and cost-effective solutions for our customers.
Learn More...
